ADDITIVE MANUFACTURING METHOD FOR DRUG DELIVERY DEVICES
Espacenet
Family 74096005
Abstract
The invention relates to an extrusion additive manufacturing method for forming a drug delivery device. The method comprises providing a first drug delivery material comprising a first major excipient with a first melting range and a first melting peak. The method further comprises extruding the first delivery material at an extrusion temperature that is within the melting range of the first major excipient.
Inventors 2
- Niels Ouwerkerk Aachen author as filed: Ouwerkerk, Niels
- Kirsten J. M. Schimmel Aachen author as filed: Schimmel, Kirsten Johanna Maria
Inventors are linked to an Aachen author when surname and first name match exactly one author.
Applicants
- DOSER IP B.V.
- ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC GBS Leiden
Cited papers 2 in the database
Non-patent literature as cited (6)
- - V. JANNIN ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 466, 2014, pages 109 - 121
- - K.C. PANIGRAHI ET AL., FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 4, 2018, pages 102 - 108
- - "Handbook Pharmaceutical Excipients", pages: 722 - 726
- - SEOANE-VIAÑO IRIA ET AL: "3D printed tacrolimus suppositories for the treatment of ulcerative colitis", ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 16, no. 1, 9 July 2020 (2020-07-09), NL, pages 110 - 119, XP055818572, ISSN: 1818-0876, DOI: 10.1016/j.ajps.2020.06.003
- - OKWUOSA TOCHUKWU C ET AL: "A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets", PHARMACEUTICAL RESEARCH, SPRINGER US, NEW YORK, vol. 33, no. 11, 9 August 2016 (2016-08-09), pages 2704 - 2712, XP036066126, ISSN: 0724-8741, [retrieved on 20160809], DOI: 10.1007/S11095-016-1995-0
- - SVENSSON A ET AL: "Hydration of an amphiphilic excipient, Gelucire� 44/14", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 281, no. 1-2, 1 August 2004 (2004-08-01), NL, pages 107 - 118, XP093129677, ISSN: 0378-5173, Retrieved from the Internet <URL:https://hal.science/hal-00015990/document> DOI: 10.1016/j.ijpharm.2004.06.005